William Blair Increases Earnings Estimates for Genmab A/S

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings per share (EPS) estimates for Genmab A/S in a research report issued on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $1.62 for the year, up from their prior forecast of $1.61. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Other analysts have also issued reports about the company. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Finally, Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Stock Down 0.7%

Shares of GMAB traded down $0.17 during trading hours on Tuesday, reaching $21.85. 568,952 shares of the company traded hands, compared to its average volume of 1,251,597. The stock has a fifty day simple moving average of $21.13 and a 200 day simple moving average of $20.77. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $28.56. The stock has a market capitalization of $14.01 billion, a PE ratio of 12.41, a price-to-earnings-growth ratio of 6.64 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the period. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after purchasing an additional 1,464 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after purchasing an additional 1,070 shares during the period. Barclays PLC raised its holdings in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Genmab A/S in the 4th quarter worth about $60,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.